181 results about "Viral genomes" patented technology

The invention relates to the technical field of agricultural biology, and particularly provides a dsRNA nanocrystallization preparation for preventing and treating areca yellows as well as a preparation method and application of the dsRNA nanocrystallization preparation. Areca yellows are a destructive disease caused by areca symptomless virus type 1 (APV1), eight key target gene segments of an APV1 virus genome are screened, specific double-stranded RNA is designed, a nano-carrier is used for wrapping and delivering a dsRNA mixture obtained by transcription of the eight target gene segments, and the areca yellows are obtained by screening. And a nanocrystallization preparation for improving the environmental stability and RNA interference efficiency of the dsRNA is prepared. Experimental results show that the nanocrystallization preparation can effectively inhibit the key gene expression of APV1 virus, reduce the virus load and improve the resistance of areca catechu to yellows. The invention provides an accurate, efficient and environment-friendly biological prevention and control strategy, and has a wide agricultural application prospect.

The invention discloses a method for quickly rescuing bovine coronavirus epidemic strains and application of the method. The bovine coronavirus SHZ isolate is subjected to efficient segmented cloning, the obtained segment and a Linker sequence are subjected to a cyclic polymerase extension reaction, and the obtained reaction product can be directly transfected to 293T cells for virus packaging without purification. Different from a traditional method, the method does not need to amplify full-length virus cDNA clone by means of bacteria and yeast, but directly obtains a sufficient amount of preliminary products through PCR, and avoids the problems of instability and low efficiency when partial sequences of a virus genome proliferate in a bacteria or yeast host. By adopting the reverse genetic system, the recombinant bovine coronavirus expressing the foreign protein is successfully rescued, a brand new technical platform is provided for dynamic visualization research of in-vivo and in-vitro replication of the virus, and an efficient and flexible tool is also provided for virology research, development of virus vector vaccines and screening of antiviral drugs.

The present invention relates to methods for producing a preparation comprising recombinant AAV (rAAV), such methods comprising a step of mechanical lysis on mammalian producer cells, and methods for increasing the viral genome titre and / or capsid titre of a preparation comprising recombinant adeno-associated virus, related uses, and preparations obtained by or obtainable by the methods.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

Disclosed herein are prokaryotic homologs of viperin (pVips), and nucleotide and nucleoside analogs produced from pVips. These nucleotide and nucleoside analogs stop nucleotide chain synthesis and provide host cells with resistance to viral infections by targeting actively replicating viral genome. Further, these nucleotide and nucleoside analogs decrease DNA replication in malignant cells. Further disclosed are methods of identifying pVips, and nucleotide and nucleoside analogs produced thereof.

The invention provides a capture primer group and a kit for targeted Salivirus genome sequencing and application of the capture primer group and the kit, and belongs to the technical field of genome sequencing. The targeted capture primer group of the Salivirus virus genome comprises a primer 1 and a primer 2, the nucleotide sequence of the primer 1 is as shown in SEQ ID NO. 1, and the nucleotide sequence of the primer 2 is as shown in SEQ ID NO. 2. According to the invention, a universal reverse transcription oligo-T primer and the Salivirus specific primer group provided by the invention are put into the reverse transcription step at the same time, so that not only is a macro transcription effect achieved, but also a Salivirus sequence in a sample is synchronously identified for specific capture. According to the method, the complete Salivirus genome sequence can be efficiently obtained, and the method has good coverage and sequencing adaptability to the virus genome.

Nucleotide compositions, recombinant vectors, and recombinant viral genomes are disclosed that include a modified horseradish peroxidase (HRP) gene sequence, as well as recombinant viruses that have the modified HRP gene sequence incorporated into the viral genome thereof. The recombinant viruses are utilized in an HRP-based assay to analyze the neutralization potential of candidate antiviral agents, such as antiviral antibodies.

The invention discloses a different-length genome sequence coding method based on improved self-attention and Mamba double modules, and relates to a different-length genome sequence coding method. The invention aims to solve the problem that a genome sequence cannot be reasonably input into a neural network model in the prior art. The method comprises the following steps: in a data processing sequence feature extraction process, extracting kmer position feature information, kmer centrality feature information and inter-kmer relevance feature information of genome sequences with different lengths; in the pre-training process, a model based on improved self-attention and Mamba double modules is constructed, a sequence coding model can capture universal features of genome sequences through mask pre-training, and universal representation vectors of the same dimension of the genome sequences of different lengths are obtained; in the fine tuning process, by using specific biological task data for fine tuning training, the coding model can be better matched with various virus-based genomes such as virus recognition, virus host and virus lifestyle recognition. The invention belongs to the technical field of deep learning and gene engineering.

Provided herein are polynucleotides comprising a coding sequence for expression of a fibroblast growth factor 21 (FGF21) pathway activating agent. Also provided are vectors, recombinant viral genomes, and recombinant virus compositions comprising said polynucleotides, as well as associated methods.

The invention belongs to the field of biological medicine, and particularly relates to a recombinant adenovirus and application thereof. The technical problem to be solved by the invention is to provide the recombinant adenovirus with good tumor inhibition effect and high efficiency. The technical scheme of the invention is a recombinant adenovirus. The recombinant adenovirus is a replication-defective adenovirus, and an exogenous nucleic acid fragment is operably inserted into a viral genome; the exogenous nucleic acid fragment is a coding gene of human p53 protein, a coding gene of GM-CSF and a coding gene of RGD. The coding gene of the human p53 protein, the coding gene of the GM-CSF and the coding gene of the RGD are jointly constructed into the replication-deficient adenovirus, so that the adenovirus with multiple advantages is obtained, the tumor cell killing efficiency is improved by 2-4 times compared with that before recombination, and a new effective choice is provided for tumor immunotherapy.

The invention relates to a helper adenovirus genome wherein expression of one or more of the adenoviral early E1 genes, E2 genes including DNA-binding protein (DBP), pre-terminal protein (pTP) and DNA polymerase, or production of functional proteins are regulated. The invention also relates to a process for delivery of the helper-dependent or gutless adenovirus vector genome and modulating replication of the helper virus DNA in the manufacturing cells, in which to allow a sufficient length of time before excision, cutting, or recombination to removal of the viral packaging signal DNA sequence from the helper adenovirus genome prior to induction of viral DNA replication, and expression of helper proteins that are required for adenovirus capsid particle formation and packaging, or encapsidation, of the helper-dependent or gutless adenovirus vector genomes, while preventing the packaging, or encapsidation, of the helper adenoviral genome into preform adenoviral capsids.

The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or self-replicating RNAs, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and / or treating various health conditions.

This invention discloses a chikungunya virus genome fragment armored RNA reference, its preparation method, and its application. The preparation process involves the following steps: (1) constructing the prokaryotic expression backbone vector pACYCAR; (2) cloning the CKV genome fragment CKA (nt17-2276); (3) constructing the prokaryotic expression vector pACYCAR-CKA; (4) inducing the expression of armored RNA; and (5) purifying the armored RNA. This invention solves the technical problems of high biosafety risk, poor stability, and insufficient gene fragment coverage in existing CKV nucleic acid detection references. It fills the gap in the lack of high-quality references for CKV detection.

The invention discloses a primer group and a kit for detecting a new bunyavirus genome and application of the primer group and the kit. The primer group comprises a primer group I and a primer group II, wherein the primer group I comprises nucleotide sequences as shown in SEQ ID NO.1-39; and the primer group II comprises a nucleotide sequence as shown in SEQ ID NO.40-77. The primer group I comprises a nucleotide sequence as shown in SEQ ID NO.7. The primer group can be used for amplifying the whole genome of various strains of the new bunyavirus. According to the application, nucleic acid of the new bunyavirus in a sample is obtained by using an efficient and stable nucleic acid extraction technology, cDNA is synthesized by using an optimized reverse transcription system, then two multiple PCR primer pools are designed by using an imbricate amplification principle, whole-genome segmented amplification is performed on the cDNA by using high-fidelity enzyme, and the cDNA is amplified by using high-fidelity enzyme to obtain the new bunyavirus. And finishing the detection of the new bunyavirus genome in combination with a three-generation sequencing platform. The method can accurately analyze nucleotide mutation through sequence alignment, has the characteristics of simplicity and convenience in operation, high efficiency, rapidness, high specificity and high accuracy, and provides a powerful tool for monitoring, prevention and control and research of the new bunyavirus.

The invention provides a norovirus genome splicing method and device, a medium and a product. The method comprises the following steps: acquiring a norovirus gene database, wherein the norovirus gene database comprises a non-structural protein coding region sub-library and a capsid protein coding region sub-library; obtaining original sequencing data; performing quality control on the original sequencing data to obtain screened sequencing data; comparing and assembling the screened sequencing data with the non-structural protein coding region sub-library, and determining at least one first recombinant coding region; and comparing and assembling the screened sequencing data with the capsid protein coding region sub-library, and determining at least one second recombinant coding region, and splicing the at least one first recombinant coding region and the at least one second recombinant coding region to obtain a recombinant genome sequence. Through the technical scheme disclosed by the invention, efficient and accurate splicing of the recombinant norovirus genome sequence is realized, and the assembly accuracy and efficiency of the recombinant norovirus genome sequence are improved.

The invention discloses establishment and application of a flavivirus replication-dependent RNA (Ribonucleic Acid) recombination experiment system, and belongs to the technical field of biology. The RNA recombination system comprises two components: a tembusu virus E gene deleted subgenome replicon CQW1-delta E, and a defective virus genome CQW1-delta NS1 or MM1775-delta NS1 with a part of NS1 gene sequence deleted. The two components cannot generate progeny viruses independently, but after the two components are co-transfected, a large number of recombinant progeny viruses can be generated within several days after transfection due to RNA recombination, the recombination efficiency is extremely high, continuous passage is not needed, the construction period is greatly shortened, and the production cost is saved; meanwhile, the generated progeny virus can form plaques on cells, and by means of plaque counting, the method can be applied to quantitative measurement of the RNA recombination efficiency and analysis of key factors influencing the tembusu virus RNA recombination.

The invention discloses a nucleic acid molecule which comprises an open reading frame for coding an EBV antigen, and the EBV antigen is a specific antigen which is contained in a diseased cell of an EBV related disease, is coded by an EBV virus genome and is in a cell and on a cell membrane; the EBV antigen comprises LMP1, LMP2A, LMP2B, EBNA-LP, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA4, EBNA5, EBNA6, EBNA7 and EBNA8, as well as lipid nanoparticles containing nucleic acid molecules, a pharmaceutical composition and application thereof, and belongs to the technical field of biology. The nucleic acid molecule, the mRNA, the composition containing the nucleic acid molecule, and the lipid nanoparticles can significantly increase the number of tumor specific immune cells, effectively activate immune response, and significantly inhibit tumor growth, and have significant anti-tumor activity for nasopharynx cancer and lymphoma.

The present disclosure provides materials and methods for detecting the presence of a target, such as a nucleic acid, biomolecule or biological particle, or virus genome in a sample. The present disclosure further provides point of care detection methods that cane done quickly and simply, optionally without sophisticated instrumentation. The present disclosure further provides improved methods for detecting and quantifying detection signals from various emulsions.

The disclosure relates to polynucleotides, e.g., viral genomes, encoding syntaxin-binding protein-1 (STXBP1), vectors, e.g., adeno-associated virus (AAV) particles, comprising said polynucleotides, compositions comprising said polynucleotides or vectors, and methods of making or delivering to a cell or subject. The polynucleotides, vectors, compositions, and methods of the present disclosure are useful for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a STXBP1-related disorder, e.g., STXBP1 Developmental and Epileptic Encephalopathy (DEE) and / or other STXBP1-related disorders, or at least one symptom thereof.

The invention discloses an SFTSV pseudovirus as well as a preparation method and application thereof. Based on the characteristics of high pathogenicity and transmissibility of the SFTSV, the virus infection animal experiment needs to be operated in a laboratory at the biosafety third level or above, so that the research and development of vaccines and therapeutic drugs are limited to a great extent. A novel SFTSV pseudovirus is obtained by deleting a nucleoprotein coding gene in an S gene of the SFTSV virus based on a reverse genetics technology, and the pseudovirus lacks a complete virus genome and replication ability and can be researched in a low-biosecurity-level laboratory; the pseudovirus system carries luciferase or a green fluorescent protein reporter gene, the virus load is quantified through the expression of the reporter gene, and the pseudovirus system can be used for evaluating the inhibition effect of a small-molecule inhibitor or a natural product on virus invasion; the pseudovirus can be used for simulating a natural infection process and evaluating a neutralizing antibody level induced by a vaccine. The invention provides a new development platform for discovery of anti-SFTSV drugs.

Described herein are recombinant viral genomes comprising a nucleotide sequence encoding a telomerase reverse transcriptase (TERT) operably linked to a tissue-specific and / or organ-specific promoter. Aspects described herein may be used in the treatment of conditions associated with shortened telomere length, such as pulmonary fibrosis, myocardial infarction and conditions associated therewith.

Described are optimized RNAi agents, compositions that include RNAi agents, and methods for inhibition of coronavirus (CoV) viral genome. The optimized CoV RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a SARS-CoV-2 viral genome, and the targeted portions of the genome are conserved across a variety of known coronaviruses. Pharmaceutical compositions that include one or more optimized CoV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described CoV RNAi agents to pulmonary cells, in vivo, provides for inhibition of CoV viral genome expression, including SARS-CoV-2, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including COVID-19.

The present disclosure relates to constructs, in particular lentiviral constructs, for use in expression systems for cellular and / or gene therapy applications. These constructs include viral genomes whose expression is controlled by the RNA polymerase I (Pol I) promoter.

This disclosure concerns methods of analysing and sequencing viral genomic DNA, in particular Epstein-Barr virus (EBV) genomic DNA, using viral-specific nucleic acid capture probes and long read sequencing.

The present invention is directed to a method for detecting the presence or absence of monkeypox virus (MPXV) in a biological sample, the method comprising: a) contacting the sample or nucleic acid extracted from said sample with reagents and an oligonucleotide combination capable of amplifying a target region of a monkeypox viral genome, wherein said oligonucleotide combination is selected from the group consisting of: i) a B7R oligonucleotide primer set specific for amplifying a target sequence in the B7R gene of the MPXV genome generating an MPXV amplification product comprising the sequence of SEQ ID NO:65; and ii) a G2R oligonucleotide primer set specific for amplifying a target sequence in the G2R gene of the MPXV genome generating an MPXV amplification product comprising the sequence of SEQ ID NO:63; b) performing an in vitro nucleic acid amplification reaction, wherein any MPXV nucleic acid present in the sample is used as a template to generate the MPXV amplification product corresponding to the oligonucleotide combination of i) or ii); and c) detecting the presence or absence of the MPXV amplification product generated in step b), wherein the presence of the MPXV amplification product is indicative of the presence of MPXV in the biological sample. The present invention also provides oligonucleotides which can be used in the method of the invention as primers and probes.

The invention discloses a kit for rapidly and quantitatively detecting an integrated HIV (Human Immunodeficiency Virus) previrus genome and application of the kit. The kit comprises an anchor primer in an Alu region in an HIV virus, and degenerate primers in gag, nef and LTR regions of an HIV sequence. According to the kit disclosed by the invention, after pre-amplification, the integrated copy number AU-LTR detected by the QPCR is obviously improved compared with AU-gag and AU-nef, and the capture efficiency is higher. Meanwhile, the kit provided by the invention can be used for carrying out three-generation sequencing on a detected sample with a relatively high integration level on the basis of Alu-LTR capture and detection of an integrated copy number, and can be used for carrying out sequence composition and genome position analysis on a storage library of HIV (Human Immunodeficiency Virus).

The application discloses a kind of establishment and application of flavivirus replication-dependent RNA recombination experimental system, belong to the field of biotechnology.The RNA recombination system includes two components: tanbusu virus E gene deletion subgenomic replicon CQW1-ΔE, and the defective virus genome CQW1-ΔNS1 or MM1775-ΔNS1 missing partial NS1 gene sequence.The two components cannot produce progeny virus alone, but after co-transfection, due to RNA recombination, a large number of recombinant progeny viruses can be produced within a few days after transfection, the recombination efficiency is extremely high, and continuous passage is not required, greatly shortening the construction cycle and saving production costs;At the same time, the progeny virus can form plaques on cells, and the efficiency of RNA recombination can be quantitatively measured by plaque counting, and the key factors affecting tanbusu virus RNA recombination can be analyzed.

The invention relates to a helper adenovirus genome wherein expression of one or more of the adenoviral early E1 genes, E2 genes including DNA-binding protein (DBP), pre-terminal protein (pTP) and DNA polymerase, or production of functional proteins are regulated. The invention also relates to a process for delivery of the helper-dependent or gutless adenovirus vector genome and modulating replication of the helper virus DNA in the manufacturing cells, in which to allow a sufficient length of time before excision, cutting, or recombination to removal of the viral packaging signal DNA sequence from the helper adenovirus genome prior to induction of viral DNA replication, and expression of helper proteins that are required for adenovirus capsid particle formation and packaging, or encapsidation, of the helper-dependent or gutless adenovirus vector genomes, while preventing the packaging, or encapsidation, of the helper adenoviral genome into preform adenoviral capsids.

The invention discloses a coronavirus attenuated strain, a vaccine as well as a preparation method and application of the coronavirus attenuated strain. Compared with a natural strain, the coronavirus attenuated strain disclosed by the invention at least comprises deletion of a No.5 stem loop (Stem-loop 5, SL5) from the 131 site to the 350 site of a 5 '-non-coding region (5' UTR) or mutation of any nucleotide maintaining a stem loop structure in a second stem loop from the 175 site to the 299 site of the SL5; compared with a natural strain, the virulence of the SL5-deleted mutant virus strain is obviously reduced; the SL5-deficient mutant virus strain has better genetic stability, and the carried virus genome has no risk of being integrated into the host cell genome. Therefore, the coronavirus attenuated strain disclosed by the invention can be used as an attenuated live vaccine for preventing coronavirus infection, and has a good application prospect.